drugset / Trial / NCT01882400
Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy
NaSingle-groupOpen-labelPrevention
Summary
By supplying an adequate amount of calcium and vitamin D with the addition of weekly bisphosphonate, the investigators will be able to increase bone mass and decrease the incidence of fragility fractures in these children with muscular dystrophy. The investigators think this treatment will also decrease the intensity of pain frequently present in these patients and slow the progression of scoliosis.
Timeline
- Start
- 2001-05
- Primary completion
- 2007-09
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alendronic Acid | Small molecule | — | Oral |
| Subject | Risedronate | Small molecule | — | Oral |
| Background | Calcium carbonate | Other / unclassified | — | — |
| Background | Vitamin D | Other / unclassified | — | — |